Sol Atriyal Apendiks Trombüsü Medikal Tedavisi

Biase LD, Burkhardt JD, Mohanty P, et al. Left atrial appendage an underrecognized trigger site of atrial fibrillation. Circulation 2010;122(2):109-118. doi:10.1161/CIRCULATIONAHA.109.928903.

Krishnamurthi RV, Feigin VL, Forouzanfar MH, et al. Global and regional burden of first‐ever ischaemic and haemorrhagic stroke during 1990‐ 2010: findings from the Global Burden of Disease Study 2010. Lancet Glob Health. 2013;1(5): 259‐281. doi:10.1016/S2214‐109X(13)70089‐5

Raskob GE, Angchaisuksiri P, Blanco AN, et al. Thrombosis: a major contributor to global disease burden. Arterioscler Thromb Vasc Biol. 2014;34(11): 2363‐2371. doi:10.1161/ATVBAHA.114.304488

Adams HP Jr, Bendixen BH, Kappelle LJ, et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke. 1993;24(1): 35‐41. doi:10.1161/01.STR.24.1.35

Lin HJ, Wolf PA, Kelly‐Hayes M, et al. Stroke severity in atrial fibrillation. The Framingham Study. Stroke. 1996;27(10): 1760‐1764. doi:10.1161/01.STR.27.10.1760

Blackshear JL, Odell JA. Appendage obliteration to reduce stroke in cardiac surgical patients with atrial fibrillation. Ann Thorac Surg 1996;61(2): 755–759. doi: 10.1016/0003-4975(95)00887-X

Yiin GS, Howard DP, Paul NL, et al. Age‐specific incidence, outcome, cost, and projected future burden of atrial fibrillation‐related embolic vascular events: a population‐based study. Circulation. 2014;130(15): 1236‐1244. doi:10.1161/CIRCULATIONAHA.114.010942

Aguilar MI, Hart R, Pearce LA. Oral anticoagulants versus antiplatelet therapy for preventing stroke in patients with non‐valvular atrial fibrillation and no history of stroke or transient ischemic attacks. Cochrane Database Syst Rev. 2007;18(3): CD006186. doi:10.1002/14651858. CD006186.pub2

Kirchhof P, Camm AJ, Goette A, et al. Early rhythm‐control therapy in patients with atrial fibrillation. N Engl J Med. 2020;383(14): 1305‐1316. doi:10.1056/NEJMoa2019422

G. Corrado, G. Tadeo, S. Beretta, et al. Atrial thrombi resolution after prolonged anticoagulation in patients with atrial fibrillation. Chest. 1999;115(1): 140–143. doi: 10.1378/chest.115.1.140

Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146(12): 857-867. doi: 10.7326/0003-4819-146-12-200706190-00007

De Caterina R, Husted S, Wallentin L, et al. Vitamin K antagonists in heart disease: current status and perspectives (Section III). Position paper of the ESC working group on thrombosis Task Force on anticoagulants in heart disease. Thromb Haemost. 2013;110(6): 1087-1107. doi: 10.1160/TH13-06-0443

Apostolakis S, Sullivan RM, Olshansky B, et al. Factors affecting quality of anticoagulation control among patients with atrial fibrillation on warfarin: the SAMe-TT(2)R(2) score. Chest 2013;144(5): 1555-1563. doi: 10.1378/chest.13-0054

Klein AL, Grimm RA, Murray RD, et al. Assessment of cardioversion using transesophageal echocardiography investigators. Use of transesophageal echocardiography to guide cardioversion in patients with atrial fibrillation. N Engl J Med. 2001;344(19): 1411-1420. doi: 10.1056/NEJM200105103441901

Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur J Cardiothorac Surg. 2016;37(38): 2893-2962. doi: 10.1093/eurheartj/ehw210

Ruff TC, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. The Lancet. 2014;383(9921): 955–962. doi: 10.1016/S0140-6736(13)62343-0

Birman-Deych E, Radford MJ, Nilasena DS, et al. Use and effectiveness of warfarin in Medicare benefi ciaries with atrial fibrillation. Stroke. 2006;37(4): 1070–1074. doi: 10.1161/01.STR.0000208294.46968.a4

Hylek EM, Evans-Molina C, Shea C, et al. Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. Circulation. 2007;115(21): 2689–2696. doi: 10.1161/CIRCULATIONAHA.106.653048

Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12): 1139–1151. doi: 10.1056/NEJMoa0905561

Giugliano PR, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369(22): 2093–2104. doi: 10.1056/NEJMoa1310907

Bernhardt P, Schmidt H, Hammerstingl C, et al. Fate of left atrial thrombi in patients with atrial fibrillation determined by transesophageal echocardiography and cerebral magnetic resonance imaging. Am J Cardiol. 2004;94(6): 801–804. doi: 10.1016/j.amjcard.2004.06.010

Hammerstingl C, Potzsch B, Nickenig G. Resolution of giant left atrial appendage thrombus with rivaroxaban. Thromb Haemost. 2013;109(4): 583–584. doi: 10.1160/TH12-11-0821

Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11): 981–992. doi: 10.1056/NEJMoa1107039

Kawakami T, Kobayakawa H, Ohno H, et al. Resolution of left atrial appendage thrombus with apixaban. Thromb J. 2013;11(1):26. doi: 10.1186/1477-9560-11-26

Dobashi S, Fujino T, Ikeda T. Use of apixaban for an elderly patient with left atrial thrombus. BMJ Case Rep. 2014;bcr2014203870. doi: 10.1136/bcr-2014-203870

Mitamura H, Nagai T, Watanabe A, et al. Left atrial thrombus formation and resolution during dabigatran therapy: a Japanese Heart Rhythm Society report. J Arrhythm. 2015;31(4):226–231. doi: 10.1016/j.joa.2014.12.010

Vidal A, Vanerio G. Dabigatran and left atrial appendage thrombus. J Thromb Thrombolysis. 2012;34(4): 545–547. doi: 10.1007/s11239-012-0747-1

Tabata E, Yasaka M, Wakugawa Y, et al. Increase in the Size of an Intracardiac Thrombus during Dabigatran Therapy (110 mg b.i.d.) in an Acute Cardioembolic Stroke Patient. Cerebrovasc Dis Extra. 2013;3(1):78–80. doi: 10.1159/000351137

Ferner M, Wachtlin D, Konrad T, et al. Rationale and design of the RE-LATED AF—AFNET 7 trial: REsolution of Left atrial-Appendage Thrombus—Effects of Dabigatran in patients with Atrial Fibrillation. Clin Res Cardiol. 2016;105(1): 29-36. doi: 10.1007/s00392-015-0883-7

Patel MR, Mahaff ey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10): 883–891. doi: 10.1056/NEJMoa1009638

Eriksson BI, Borris LC, Friedman RJ, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med. 2008;358(26): 2765–2775. doi: 10.1056/NEJMoa0800374

Turner M, Solarz D. Left atrial thrombus formation after brief interruption of rivaroxaban. Am J Emerg Med. 2016;34(1):116. doi: 10.1016/j.ajem.2015.05.030

The EINSTEIN Investigators; Bauersachs R, Berkowitz SD, Brenner B, et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010;363(26): 2499–2510. doi: 10.1056/NEJMoa1007903

Zylla MM, Pohlmeier M, Hess A, et al. Prevalence of intracardiac thrombi under phenprocoumon, direct oral anticoagulants (dabigatran and rivaroxaban), and bridging therapy in patients with atrial fibrillation and flutter. Am J Cardiol. 2015;115(5): 635–640. doi: 10.1016/j.amjcard.2014.12.016

Turner M, Solarz D. Left atrial thrombus formation after brief interruption of rivaroxaban. Am J Emerg Med. 2016;34(1):116. doi: 10.1016/j.ajem.2015.05.030

Serra W, Li Calzi M, Coruzzi P. Left atrial appendage thrombosis during therapy with rivaroxaban in elective cardioversion for permanent atrial fibrillation. Clin Pract. 2015;5(3): 78. doi: 10.4081/cp.2015.788

Biller K, Biller B, Findeisen H, et al. Resolution of left atrial appendage thrombi: No difference between phenprocoumon and non‐vitamin K‐dependent oral antagonists. Clin Cardiol. 2022;45(6): 650-656. doi: 10.1002/clc.23823